Background/Aims: The effect of entecavir (ETV) in treatment-naïve chronic hepatitis B (CHB) is well established. This study aimed to assess the efficacy of ETV treatment at 0.5 mg/day in ETV-switch and ETV-retreatment groups of CHB patients without lamivudine (LMV)-resistance from LMV monotherapy. Methods: Study subjects included 350 CHB patients who had been treated with 0.5 mg/day of ETV for at least 6 months. Patients were divided into two groups: an LMV-naïve group (n = 263) and an LMV-experienced group (n = 87). The LMV-experienced group was further subdivided into an ETV-switch group (n = 43) and an ETV-retreatment group (n = 44) defined by the period between stopping LMV and restarting ETV. Results: There were no significant differences in mean age, sex ratio, prevalence of liver cirrhosis and hepatitis B e antigen (HBeAg) positivity between the LMV-naïve and -experienced groups. However, the LMV-naïve group had higher aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels and a shorter ETV treatment duration than the LMV-experienced group. There were also distributional differences in the hepatitis B virus (HBV) DNA levels of LMV-naïve and -experienced patients prior to ETV treatment. After ETV treatment, there were no significant differences between the two groups in the rates of undetectable HBV DNA at 6, 12 and 18 months; HBeAg loss and seroconversion; normalization of ALT; virologic breakthrough; and ETV-genotypic resistance. Lastly, the effect of ETV did not differ between the ETV-switch and -retreatment groups. Conclusions: The effect of ETV in the LMV-experienced group without LMV-resistance did not differ from that in the LMV-naïve group. Furthermore, there was no difference in the effect of ETV between the ETV-switch and -retreatment groups. (Korean J Med 2013;84:810-817) 
In a multivariate analysis, HBV DNA level prior to ETV treatment was the only predictive factor for virologic response in the LMV-naïve group. There was no predictive factor for virologic response in the LMV-experienced group. ETV, entecavir; LMV, lamivudine; OR, odds ratio; CI, confidential interval. 
